Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer
NCT05055947
·
clinicaltrials.gov ↗
COMPLETED
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
DRUG:
First line EC/EP+Atezolizumab
Sponsor
Hunan Province Tumor Hospital